WO1989000848A1 - Method for the treatment of body tissues and the administration of drugs thereto - Google Patents
Method for the treatment of body tissues and the administration of drugs thereto Download PDFInfo
- Publication number
- WO1989000848A1 WO1989000848A1 PCT/US1987/003505 US8703505W WO8900848A1 WO 1989000848 A1 WO1989000848 A1 WO 1989000848A1 US 8703505 W US8703505 W US 8703505W WO 8900848 A1 WO8900848 A1 WO 8900848A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxygenated
- perfluorocarbon
- drugs
- tissue
- fluid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention relates to a method for a treatment of and the administration of drugs to body tissues and surfaces.
- this invention particularly relates to the treatment of structures such as the skin or mucosa which are in need of enhanced or supplemental oxygen supply.
- This invention also relates to the treatment of individuals or tissues within individuals which may additionally or alternatively require the administration of drugs.
- Yet another long sought goal of medical science is ' an effective, non-invasive technique for the percutaneous administration of drugs.
- Most known methods are not well suited to be used by patents (e.g., intraveneous injection) or result in poor absorption and utilization of the drug (e.g., enceric administration). It is therefore an object of this invention to provide a method of treatment which will supplement or restore the-;; oxygen supply to damaged tissues. It is also an object of this invention to provide a method of treatment which facilitates the effective percutaneous administration of drugs which can be useful in the treatment of disease and especially useful in the treatment of damaged or diseased mucosa or skin.
- damaged bodily tissue is treated by oxygenating a pharmaceutically acceptable liquid with a therapeutically effective amount of oxygen and then applying the oxygenated liquid to the affected tissue.
- another therapeutic agent is dissolved or suspended in the liquid in addition to • or in place of oxygen.
- This therapeutic agent may be selected from an exceptionally wide variety of drugs including antibiotics, anti-inflamatories or mixtures of such agents or drugs.
- Another highly useful group of therapeutic agents are those which are useful in treating skin diseases such as acne, psoriasis, angina pectoris or skin cancers.
- perfluorinated hydrocarbons are generally insoluble in water it is highly preferred that an aqueous emulsion of the perfluorinated hydrocarbons to be used.
- Fluosol-DA Green Cross
- Oxypherol-ET Alpha Therapeutic Corporation. The composition of Oxypherol-ET is set forth in Table II.
- the Oxypheral-ET formulation may be modified by increasing the hydroxyethyl starch level to from 5- to 20%.
- the oxygenation of the perfluorocarbon or perfluorocarbon emulsion used in the process of the present invention can be carried out by exposing the fluid to an atmosphere of at least 75% oxygen, although an atmosphere of at least 95% oxygen is preferred. This is most effectively accomplished by bubbling oxygen at slightly greater than atmqspheric pressure through the perfluorocarbon. Once oxygenated, the perfluorocarbon or perfluorocarbon emulsion may be applied directly to damaged tissue.
- Perfluorocarbon preparations are known to be able to dissolve at least 40% of oxygen and it is desirable to use fully saturated preparations when treating oxygen starved tissues. However, even oxygen starved tissues benefit substantially from the use of 25% solutions.
- the oxygenated fluid should be applied to the affected tissue at regular intervals to obtain maximum therapeutic effect. It is expected that it will be necessary to reapply the oxygenated fluid to the affected tissue 2 to 6 times each day.
- topical or percutaneous administration of drugs can be accomplished with special advantage by the process of the present invention and the absorption of drugs is accomplished with suprising effectiveness.
- the affected tissue has suffered injury as a result of a trama or where secondary infection is present or seriously possible, it will be advisable to include a therapeutic concentration of an appropriate antibotic in the oxygenated perfluorocarbon fluid.
- Therapeutic concentrations of some suitable topical antibotics are set forth in Table III.
- Polymyxin B 0.5-1.5% by wt.
- an anti-inflamatory agent may be included in the oxygen-containing liquid which is used in the present invention.
- an anti-inflamatory agent may be included in the oxygen-containing liquid which is used in the present invention.
- hydrocortisone 0.5 to 1.5% by weight
- Other therapeutic agents which may be used include nordihydroquaiaretic acid and its derivatives, the usefulness of which is described in co-pending United States Patent Application No. 699,923, filed February 2, 1985.
- a wide variety of drugs can be administered with exceptional effectiveness through healthy skin by the process of the present invention. This process, therefore, has broad application in the percutaneous administration of drugs without regard to its usefulness as an oxygen supply technique.
- a bedsore may be treated by applying to it sufficient volume of oxygenated Oxypherol-ET to completely over the sore.
- the sore can be seen to begin to heal within 2 weeks and heal completely in about 4 weeks as the above described procedure is repeated every 12 hours.
- nitroglycern can be dissolved in the above-mentioned perfluorocarbon composition and applied in a patch on the skin of a patient suffering from angina pectoris. This procedure can provide immediate and sustained relief to the patient.
- Oxypherol-ET oxygenated Oxypherol-ET to completely over the sore.
- the sore can be seen to begin to heal within 2 weeks and heal completely in about 4 weeks as the above described procedure is repeated every 12 hours.
- nitroglycern can be dissolved in the above-mentioned perfluorocarbon composition and applied in a patch on the skin of a patient suffering from angina pectoris. This procedure can provide immediate and sustained relief to the patient.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
An oxygenated fluid is applied to damaged bodily tissue, thereby making oxygen available to the tissue. Perflurinated hydrocarbons may be oxygenated and used in this process. Various therapeutic agents may be mixed with the oxygenated fluid and administered to the damaged tissue.
Description
METHOD FOR THE TREATMENT OF BODY TISSUES AND THE ADMINISTRATION OF DRUGS THERETO
The invention relates to a method for a treatment of and the administration of drugs to body tissues and surfaces. In one embodiment, this invention particularly relates to the treatment of structures such as the skin or mucosa which are in need of enhanced or supplemental oxygen supply. This invention also relates to the treatment of individuals or tissues within individuals which may additionally or alternatively require the administration of drugs.
Medical science has long sought effective methods of treatment for body tissues which suffer from inadequate oxygen supply. Often this inadequate oxygen supply is the result of chronic circulatory problems and the like. Examples of such conditions include bed sores, diabetic skin ulcers and ulcers which are associated with atherosclerotic conditions. At other times, this oxygen starved condition can be caused by a tramatic injury which interrupts or diminishes the blood supply to a part of the body. Failure to treat these sorts of conditions can result in slow or failed healing, scarring, large scale tissue necrosis and even gangrene. Secondary infections can always be a serious problem in these situations.
Yet another long sought goal of medical science is 'an effective, non-invasive technique for the percutaneous administration of drugs. Most known methods are not well suited to be used by patents (e.g., intraveneous injection) or result in poor absorption and utilization of the drug (e.g., enceric administration).
It is therefore an object of this invention to provide a method of treatment which will supplement or restore the-;; oxygen supply to damaged tissues. It is also an object of this invention to provide a method of treatment which facilitates the effective percutaneous administration of drugs which can be useful in the treatment of disease and especially useful in the treatment of damaged or diseased mucosa or skin.
According to this invention, damaged bodily tissue is treated by oxygenating a pharmaceutically acceptable liquid with a therapeutically effective amount of oxygen and then applying the oxygenated liquid to the affected tissue. In an alternate embodiment of the invention another therapeutic agent is dissolved or suspended in the liquid in addition to • or in place of oxygen. This therapeutic agent may be selected from an exceptionally wide variety of drugs including antibiotics, anti-inflamatories or mixtures of such agents or drugs. Another highly useful group of therapeutic agents are those which are useful in treating skin diseases such as acne, psoriasis, angina pectoris or skin cancers.
There are several -compounds which are known to be pharmaceutically acceptable liquids capable of dissolving therapeutically effective amounts of oxygen. These compounds have in the past been known to be useful only as blood replacements. That is, they are used as a temporary supplement to the body's supply of blood when blood is lost through tramatic injury or surgery. These compounds are almost always perfluorinated hydrocarbons. A list of perfluorinated hydrocarbons which can be used in the process of the present invention is set forth in Table I.
TABLE I
perfluordecalin perfluoro, 1-methydecalin perfluorotributylamine perfluorotribyltetrahydrofuran perfluoropolyether perfluorotripropylamine perfluorodihexylether perfluoro,4-methyloctehydroquinolidizine
Because perfluorinated hydrocarbons are generally insoluble in water it is highly preferred that an aqueous emulsion of the perfluorinated hydrocarbons to be used. A number of emulsified perfluorinated hydrocarbons .are commercially available as blood replacements. Examples include Fluosol-DA (Green Cross) a mixture of fluorinated decalin and perfluor¬ inated tripropylamine. Another highly preferred commercially available material is Oxypherol-ET (Alpha Therapeutic Corporation). The composition of Oxypherol-ET is set forth in Table II.
*A polyoxyethylene-polyoxypropylene. e ulsifier.
While these commercially available perfluorocarbon preparations are well suited to use in this invention/ it is often helpful to increase their viscosity by using a greater proportion of thickening agents. Thus, the Oxypheral-ET formulation may be modified by increasing the hydroxyethyl starch level to from 5- to 20%.
The oxygenation of the perfluorocarbon or perfluorocarbon emulsion used in the process of the present invention can be carried out by exposing the fluid to an atmosphere of at least 75% oxygen, although an atmosphere of at least 95% oxygen is preferred. This is most effectively accomplished by bubbling oxygen at slightly greater than atmqspheric pressure through the perfluorocarbon. Once oxygenated, the perfluorocarbon or perfluorocarbon emulsion may be applied directly to damaged tissue.. Perfluorocarbon preparations are known to be able to dissolve at least 40% of oxygen and it is desirable to use fully saturated preparations when treating oxygen starved tissues. However, even oxygen starved tissues benefit substantially from the use of 25% solutions.
The oxygenated fluid should be applied to the affected tissue at regular intervals to obtain maximum therapeutic effect. It is expected that it will be necessary to reapply the oxygenated fluid to the affected tissue 2 to 6 times each day.
Owing to the physical and chemical characteristics of the perfluorinated hydrocarbons used in the method of the present invention, topical or percutaneous administration of drugs can be accomplished with special advantage by the process of the present invention and the absorption of drugs is accomplished with suprising effectiveness. Thus, where the
affected tissue has suffered injury as a result of a trama or where secondary infection is present or seriously possible, it will be advisable to include a therapeutic concentration of an appropriate antibotic in the oxygenated perfluorocarbon fluid. Therapeutic concentrations of some suitable topical antibotics are set forth in Table III.
TABLE III
Bactracin 400-600 units/gm
Chloramphenicol 0.5-1.5% by wt.
Gentamycin 0.5-1.5% by wt.
Polymyxin B 0.5-1.5% by wt.
Natamycin 3.0-7.0% by wt.
Oxytetracycline 1.0-2.0% by wt
Similarly, if inflamation of the affected tissues is or may be a significant problem, an anti-inflamatory agent may be included in the oxygen-containing liquid which is used in the present invention. For example, 0.5 to 1.5% by weight of hydrocortisone may be used. Other therapeutic agents which may be used include nordihydroquaiaretic acid and its derivatives, the usefulness of which is described in co-pending United States Patent Application No. 699,923, filed February 2, 1985. Also, a wide variety of drugs can be administered with exceptional effectiveness through healthy skin by the process of the present invention. This process, therefore, has broad application in the percutaneous administration of drugs without regard to its usefulness as an oxygen supply technique.
As a non-limiting example of the present invention, a bedsore may be treated by applying to it sufficient volume of
oxygenated Oxypherol-ET to completely over the sore. The sore can be seen to begin to heal within 2 weeks and heal completely in about 4 weeks as the above described procedure is repeated every 12 hours.
In yet another example of this invention, nitroglycern can be dissolved in the above-mentioned perfluorocarbon composition and applied in a patch on the skin of a patient suffering from angina pectoris. This procedure can provide immediate and sustained relief to the patient.
oxygenated Oxypherol-ET to completely over the sore. The sore can be seen to begin to heal within 2 weeks and heal completely in about 4 weeks as the above described procedure is repeated every 12 hours.
In yet another example of this invention, nitroglycern can be dissolved in the above-mentioned perfluorocarbon composition and applied in a patch on the skin of a patient suffering from angina pectoris. This procedure can provide immediate and sustained relief to the patient.
Claims
1. A method of creating damaged bodily tissue comprising the steps of
Oxygenating a pharmaceutically acceptable fluid and
Applying the oxygenated pharmaceutically acceptable fluid to the damaged bodily tissue.
2. The process of' claim 1 wherein said pharmaceuticall~y acceptable fluid is an aqueous emulsion of a perfluoronated hydrocarbon and said tissue is skin or mucosa.
3. Th'e process of claim 2 wherein said oxygenated fluid contains at least 25.0 volume percent oxygen.
4. The process of claim 3 wherein said oxygenated fluid contains an additional therapeutic agent selected from the group consisting antibiotics, anti-inflamatory agents and mixtures of antibiotics, and anti-inflamatory agents.
5. The process of claim 3 wherein said oxygenated fluid contains an additional therapeutic agent sleeted from the group consisting of nordihydroquiraretic acid and its pharmaceutically acceptable derivatives.
6. A method of administering at least on drug to an individual requiring treatment comprising the steps of
mixing an efficacious amount of at least one drug with a perfluorocarbon compound
applying the drug mixed with the perfluorocarbon to the skin or mucosa of the individual requiring treatment.
7. The method of claim 6 wherein said perfluorocarbon is in the form of an emulsion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90983286A | 1986-09-19 | 1986-09-19 | |
US909,832 | 1986-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989000848A1 true WO1989000848A1 (en) | 1989-02-09 |
Family
ID=25427897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1987/003505 WO1989000848A1 (en) | 1986-09-19 | 1987-08-18 | Method for the treatment of body tissues and the administration of drugs thereto |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0324802A4 (en) |
JP (1) | JPH01503146A (en) |
AU (1) | AU2807689A (en) |
WO (1) | WO1989000848A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0493677A2 (en) * | 1991-01-03 | 1992-07-08 | Chiron Adatomed Pharmazeutische und Medizintechnische Gesellschaft mbH | Solution for the reattachment of a detached retina to the choroid |
EP0494974A1 (en) * | 1989-10-04 | 1992-07-22 | Alliance Pharmaceutical Corporation | Fluorocarbon emulsions containing amino acid based anti-inflammatory agents and buffer systems |
DE4221256A1 (en) * | 1992-06-26 | 1994-01-05 | Lancaster Group Ag | Galenic composition for topical use |
EP0576537A1 (en) * | 1991-03-21 | 1994-01-05 | Escalon Ophthalmics, Inc. | Debridement of bodily cavities using debridement fluids |
WO1994024223A1 (en) * | 1993-04-21 | 1994-10-27 | Gordon Stead | Thickening of fluorinated liquids |
EP0670159A1 (en) * | 1994-02-22 | 1995-09-06 | Hoechst Aktiengesellschaft | Fluorocarbon-containing oilemulsions |
US5637318A (en) * | 1992-06-26 | 1997-06-10 | Lancaster Group Ag | Dermatological agent for assisting the transport of oxygen in the skin |
US5641509A (en) * | 1992-06-26 | 1997-06-24 | Lancaster Group Ag | Preparation for topical use |
US5643601A (en) * | 1992-06-26 | 1997-07-01 | Lancaster Group Ag | Phospholipid-and fluorocarbon-containing cosmetic |
US5733939A (en) * | 1993-09-29 | 1998-03-31 | Alliance Pharmaceutical Corp. | Fluorocarbons as anti-inflammatory agents |
US5750141A (en) * | 1993-04-08 | 1998-05-12 | The University Of Queensland | Administration of vaso-active agent and therapeutic agent |
US5847009A (en) * | 1986-01-14 | 1998-12-08 | Alliance Pharmaceutical Corp. | Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions |
US5929039A (en) * | 1993-11-15 | 1999-07-27 | Baker Medical Research Institute | Method for treating cardiac dysfunction and pharmaceutical compositions useful therefor |
US20120225102A1 (en) * | 2008-11-25 | 2012-09-06 | Oxygen Biotherapeutics, Inc. | Perfluorocarbon gel formulations |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5061688A (en) * | 1988-08-19 | 1991-10-29 | Illinois Institute Of Technology | Hemoglobin multiple emulsion |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4186423A (en) * | 1976-10-01 | 1980-01-29 | Matsushita Electric Industrial Company, Limited | Solid electrolyte capacitor using oxide of Ru, Rh, Re, Os or Ir as electrolyte |
US4366169A (en) * | 1979-06-25 | 1982-12-28 | Sun Tech, Inc. | Use of perfluorocarbons as wound treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE881267A (en) * | 1980-01-18 | 1980-05-16 | Stein Karl N | METHOD FOR THE TREATMENT OF SKIN BURNS IN MAMMALS |
JPS59139252A (en) * | 1982-11-26 | 1984-08-10 | チルドレンズ・ホスピタル・メデイカル・センタ− | Ophthalimic prothsesis |
-
1987
- 1987-08-18 AU AU28076/89A patent/AU2807689A/en not_active Abandoned
- 1987-08-18 EP EP19880903116 patent/EP0324802A4/en not_active Withdrawn
- 1987-08-18 WO PCT/US1987/003505 patent/WO1989000848A1/en not_active Application Discontinuation
- 1987-08-18 JP JP1500105A patent/JPH01503146A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4186423A (en) * | 1976-10-01 | 1980-01-29 | Matsushita Electric Industrial Company, Limited | Solid electrolyte capacitor using oxide of Ru, Rh, Re, Os or Ir as electrolyte |
US4366169A (en) * | 1979-06-25 | 1982-12-28 | Sun Tech, Inc. | Use of perfluorocarbons as wound treatment |
Non-Patent Citations (1)
Title |
---|
See also references of EP0324802A4 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5847009A (en) * | 1986-01-14 | 1998-12-08 | Alliance Pharmaceutical Corp. | Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions |
US6361792B1 (en) | 1987-08-05 | 2002-03-26 | Alliance Pharmaceutical Corp. | Lipid dispersions and methods of use |
EP0494974A1 (en) * | 1989-10-04 | 1992-07-22 | Alliance Pharmaceutical Corporation | Fluorocarbon emulsions containing amino acid based anti-inflammatory agents and buffer systems |
EP0494974A4 (en) * | 1989-10-04 | 1992-09-02 | Alliance Pharmaceutical, Inc. | Fluorocarbon emulsions containing amino acid based anti-inflammatory agents and buffer systems |
EP0493677A3 (en) * | 1991-01-03 | 1992-12-23 | Adatomed Pharmazeutische Und Medizin-Technische Gesellschaft Mbh | Solution for the reattachment of a detached retina to the choroid |
EP0493677A2 (en) * | 1991-01-03 | 1992-07-08 | Chiron Adatomed Pharmazeutische und Medizintechnische Gesellschaft mbH | Solution for the reattachment of a detached retina to the choroid |
US5397805A (en) * | 1991-01-03 | 1995-03-14 | Adatomed Pharmazeutische Und Medizintechnische Gesellschaft Mbh | Treatment liquid for reapplying (unfolding) detached retina to the chorioid of the eye |
EP0576537A4 (en) * | 1991-03-21 | 1995-05-03 | Escalon Ophthalmics Inc | Debridement of bodily cavities using debridement fluids. |
EP0576537A1 (en) * | 1991-03-21 | 1994-01-05 | Escalon Ophthalmics, Inc. | Debridement of bodily cavities using debridement fluids |
WO1994000110A1 (en) * | 1992-06-26 | 1994-01-06 | Lancaster Group Ag | Galenic composition for topical use |
DE4221256A1 (en) * | 1992-06-26 | 1994-01-05 | Lancaster Group Ag | Galenic composition for topical use |
US5637318A (en) * | 1992-06-26 | 1997-06-10 | Lancaster Group Ag | Dermatological agent for assisting the transport of oxygen in the skin |
US5641509A (en) * | 1992-06-26 | 1997-06-24 | Lancaster Group Ag | Preparation for topical use |
US5643601A (en) * | 1992-06-26 | 1997-07-01 | Lancaster Group Ag | Phospholipid-and fluorocarbon-containing cosmetic |
US5750141A (en) * | 1993-04-08 | 1998-05-12 | The University Of Queensland | Administration of vaso-active agent and therapeutic agent |
WO1994024223A1 (en) * | 1993-04-21 | 1994-10-27 | Gordon Stead | Thickening of fluorinated liquids |
US5733939A (en) * | 1993-09-29 | 1998-03-31 | Alliance Pharmaceutical Corp. | Fluorocarbons as anti-inflammatory agents |
US5929039A (en) * | 1993-11-15 | 1999-07-27 | Baker Medical Research Institute | Method for treating cardiac dysfunction and pharmaceutical compositions useful therefor |
EP0670159A1 (en) * | 1994-02-22 | 1995-09-06 | Hoechst Aktiengesellschaft | Fluorocarbon-containing oilemulsions |
US20120225102A1 (en) * | 2008-11-25 | 2012-09-06 | Oxygen Biotherapeutics, Inc. | Perfluorocarbon gel formulations |
Also Published As
Publication number | Publication date |
---|---|
JPH01503146A (en) | 1989-10-26 |
EP0324802A4 (en) | 1991-07-24 |
EP0324802A1 (en) | 1989-07-26 |
AU2807689A (en) | 1989-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1989000848A1 (en) | Method for the treatment of body tissues and the administration of drugs thereto | |
CN101287457B (en) | Use of treprostinil to treat neuropathic diabetic foot ulcers | |
EP0279379B1 (en) | Interstitial administration of perfluorchemical emulsions for reoxygenation of hypoxic tumor cells | |
Bell et al. | Regional anesthesia with intravenous lidocaine | |
US4555524A (en) | Transdermal 2-(4-isobutylphenyl)-propionic acid medication and methods | |
JPS60100517A (en) | Radiation remedy for ulcer and method | |
JP2002510618A (en) | Use of polyamines to treat dermatological conditions | |
CA1302253C (en) | Use of tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis | |
JP2004521112A (en) | Use of a neurotoxic substance in manufacturing a therapeutic agent for joint pain | |
WO1985005036A1 (en) | Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch | |
CA2599718A1 (en) | Methods and pharmaceutical compositions for the treatment of neurological damage | |
US5278172A (en) | Method and composition for treating tendon or joint inflammation using a vasodilator | |
GARB et al. | Mycosis fungoides with bullous lesions: report of a case resistant to roentgen and arsenical therapy; effects of empiric therapy, partly based on laboratory investigations | |
Glick et al. | Phase I clinical trials of WR-2721 with alkylating agent chemotherapy | |
KR0145678B1 (en) | A podophyllotoxin preparation containing triglycerides | |
CN114831939B (en) | Triamcinolone acetonide acetate composition spray and preparation method thereof | |
CN1177587C (en) | Riluzole and alpha-tocopherol combination | |
CN1748758A (en) | Dragon's blood gel preparation and its preparing method | |
EP0137807A1 (en) | Antiviral composition and method for administering the same | |
JPH05194214A (en) | Wound curing promoter | |
JPH06199672A (en) | Combination drug for local medical treatment for inflammatory dermatopathy containing chloramphenicol, gentamycin and nystatin as active ingredient | |
Lund et al. | AN EVALUTION of Epidural Analgesia in Geriatric Surgery | |
RU2442565C1 (en) | Medical ointment | |
EP1291039B1 (en) | Use of a mixture of lidocaine and prilocaine and composition for tumescent local anesthesia | |
GB2088714A (en) | Pharmaceutical compositions containing allyl isothiocyanate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1988903116 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK JP KP KR NO SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWP | Wipo information: published in national office |
Ref document number: 1988903116 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1988903116 Country of ref document: EP |